Moleculin Biotech, Inc.
Moleculin Biotech, Inc. (MBRX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
mbrx · stock forecast · 4 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $2.47
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.50 | ↑ 1.30% |
1-day model range: $2.48–$2.52. Peak: $2.52 (+1.30%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · MBRX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-27 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-06-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-25 | Maxim Group | Upgrade ↑ | Hold→Buy |
| 2025-03-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-12 | Maxim Group | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Moleculin Biotech, Inc. (MBRX) stock. Of the recent 16 rating actions, 1 were upgrades and 0 were downgrades. 4 analysts currently cover MBRX.
Analyst Recommendation Trends
MBRX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$71M
↓ 17.9% YoY
Revenue Next Year
$42M
↓ 41.2% YoY
EPS This Year
$-5.11
EPS Next Year
$-3.84
↓ 24.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast MBRX EPS of $-5.11 for the current fiscal year, based on estimates from 1 analysts. The MBRX revenue forecast is $71M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The MBRX stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MBRX price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The MBRX short-term stock prediction for tomorrow is $2.50 (+1.30%).
Moleculin Biotech, Inc. trades on NASDAQ under the ticker MBRX. The MBRX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
MBRX forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month MBRX price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $2.47.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.